With the volume of procurement under the drug price plummeted, pharmaceutical companies how to do?

According to the 2019 Medical Security Development Statistics Express published earlier by the State Health Insurance Administration, by the end of 2019, 183% of the agreed purchase volume of 25 selected drugs in the pilot areas of the "4-plus-7" drug centralized belt volume was completed, and the purchase volume of selected drugs accounted for 78% of the purchase volume of drugs of the same generic name.
after the pilot nationwide expansion, all 25 generic varieties were successfully expanded, with an average reduction of 59% in the price of the expansion and a 25% reduction on the basis of the "4 plus 7" pilot.
addition, it is understood that in the provinces announced the results of the second batch of centralized procurement of national drugs, 32 of the 33 varieties of successful procurement, the average price reduction of 53%, to a high decline of 93%.
, from the results of the current volume procurement, price reduction is still the main trend of volume procurement.
that in the country, provinces, cities have become a film, 2020 with the volume of procurement every flowering, triggering a wave of drug price reduction in the environment, how should enterprises deal with? Where's the way out? Pharmaceutical companies should accelerate the differentiation and transformation in fact, with the national drug price linkage and intermediate link profits squeeze water, generic drug profits greatly reduced, a large number of domestic leading enterprises, multinational giants have begun to adjust the sales team, and reduce sales input increased research and development expenditure, such as Hengrui Pharmaceuticals, Zhengda Tianqing, Shi Pharmaceutical Group and other enterprises have clearly defined the direction of transformation of innovative drugs and high-end generic drugs, research and development costs increased year by year.
this fully proves that in the fierce market competition, learning to strengthen management and improve the level and ability of drug research and development is the main choice for pharmaceutical companies to explore a new way of development.
addition to strengthening research and development capabilities, pharmaceutical companies should also take full account of market factors (raw material prices, labor costs, etc.), control costs, to ensure the balance between drug prices and quality.
After all, the price of medical insurance payment will be the key factor to determine the interests of enterprises, some small and medium-sized enterprises that lack quality support in the competition and are at a disadvantage should accelerate the differentiation and transformation and improve the competitiveness of enterprises.
Layout of the broad off-site market off-site market, has increasingly become the focus of the layout of pharmaceutical companies, such as Pfizer, AstraZenecom, Bayer and other large foreign pharmaceutical companies, have a dedicated grass-roots market team, and in recent years is still deeply cultivated in this area.
of course, in addition to foreign-funded enterprises, domestic pharmaceutical companies in the past two years are also increasing efforts to expand the grass-roots market, each is carrying dozens, hundreds of varieties in the entire layout of the grass-roots market.
as China Resources Shuanghe said in its 2019 annual report, the company plans to continue to sink several base drug species, such as glycoquinone (chemical name: grequinone), to the grass-roots terminal.
Chenxin Pharmaceuticals also listed the development of base drugs in primary hospitals as a top priority, clearly the market center will sink.
, industry experts believe that pharmaceutical enterprises fully layout the grass-roots market can get a good development opportunity, pharmaceutical companies themselves will have a certain increase in product sales, especially slow disease treatment products.
future, how to undertake the increment of prescription exoded, to build a professional out-of-hospital drug sales and service system, pharmaceutical companies will be both an opportunity and a challenge.
In addition to developing markets in accordance with policy, non-policy markets will be more competitive, requiring regional teams to perform efficient operations in both markets, rather than being as extensive as they are now and simply based on sales performance."
For pharmaceutical companies, now is actually a good time to integrate all kinds of excellent resources in the regional market, to crude refine, to falsely save the truth, to eliminate those who are not suitable, unscionable, no ideas of personnel, integration of more development potential personnel, is the need to do immediately.
how to optimize the allocation of regional teams according to the development strategy and product strategy of pharmaceutical companies is a question that pharmaceutical companies must consider immediately.
conclusion, the future of national and provincial collection will become the norm.
And in this context, pharmaceutical companies should keep in mind the strength and flexibility, because the resources and capabilities of different pharmaceutical companies are inconsistent, do not hard to move hard speculation, must be based on their own advantages to position their own drug companies development strategy.
.